Chronic kidney disease in type 2 diabetes — compounds assessed

§4Compounds assessed

Compounds the Institute assesses in this indication, with the class of each and its overall certainty. A compound appears here whether or not the evidence supports its use, because recording that a compound has been studied and found wanting is as much part of the assessment as recording that one has not.

• Semaglutide in chronic kidney disease

  GLP-1 receptor agonist (acylated, long-acting)1 contributing trialfull monograph

  Composite kidney outcome hazard ratio 0.76 in type 2 diabetes with chronic kidney disease — FLOW was stopped early for efficacy on the recommendation of its independent data monitoring committee, which the Institute records as a source of modest effect-size…

  High
• Dulaglutide in chronic kidney disease

  GLP-1 receptor agonist, Fc-fusion protein1 contributing trialfull monograph

  Slower eGFR decline versus insulin glargine in moderate-to-severe chronic kidney disease — Renal endpoints were secondary and the trial was not event-driven.

  Low

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PMID 33567185

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.